Aptar Pharma Partners with Kali Care to Develop Real-Time Medication Management Technology
Aptar Pharma and Kali Care have announced that they entered into a partnership in order to address the challenge of monitoring adherence in ophthalmic clinical trials.
The combination of Aptar Pharma’s ophthalmic device expertise, and Kali Care’s ground-breaking digital monitoring system for ophthalmic medications, is likely to have a significant impact in reducing the costs and complexity of ophthalmic clinical trials.
Kali Care, a Silicon Valley-based technology company, provides a revolutionary sensor technology which allows clinicians to replace adherence assumptions in clinical trials with collected real-time data.
This represents the latest step for Aptar Pharma in the development of drug delivery devices and collaborations in the connected health space.
Aptar Pharma’s ability to support complex projects and meet the challenging and changing regulatory requirements was recently demonstrated by their collaboration with Allergan on launching the first FDA-approved prescription preservative-free ophthalmic multidose product (Restasis MultiDose™).
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit www.aptar.com/pharma
For more information on Aptar Pharma, please come and see us at CPhI North America booth 3102. To download the complete Press release:
